# DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia

> **NCT05158166** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 22 (actual)

## Conditions studied

- Adductor Spasmodic Dysphonia
- Voice Disorders
- Spasmodic Dysphonia

## Interventions

- **DRUG:** DaxibotulinumtoxinA

## Key facts

- **NCT ID:** NCT05158166
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-13
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-03-02
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05158166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05158166, "DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05158166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*